Because most patients with Muir–Torre syndrome are MSH2-deficient and prostate cancers with MSH2 deficiency tend to have higher Gleason scores, early detection and treatment are important for prostate cancer patients with Muir–Torre syndrome. This evidence concerns the gene MSH2 and Familial prostate cancer.